LITHICARB lithium carbonate 250mg tablet bottle Australia - English - Department of Health (Therapeutic Goods Administration)

lithicarb lithium carbonate 250mg tablet bottle

aspen pharmacare australia pty ltd - lithium carbonate, quantity: 250 mg - tablet, film coated - excipient ingredients: dextrin; lactose monohydrate; macrogol 6000; sodium starch glycollate type a; purified talc; sodium lauryl sulfate; magnesium stearate; hypromellose; maize starch - mania, both as treatment and prophylaxis; manic depressive (bipolar) illness, both as treatment and as prophylaxis; it is less effective in depressive swings. in recurrent endogenous (unipolar) depressive illness, it is highly effective as prophylaxis in a number of cases, and is probably useful as treatment, especially if there is a family history of manic depressive illness and response to lithium. in some cases of schizoaffective illness and so called chronic schizophrenia it is dramatically effective. those in the latter category who do respond have frequently had affective symptoms at some time. it is used in character or personality disorders in young people with clear evidence of cyclothymia. lithium should not be prescribed until it is certain that the manic depressive swings are established and the course of the disease certain. if the patient has two affective swings in one year, perhaps in opposite directions, and associated with a positive family history, it should certainly be seriously considere

Gaviscon Extra Chewable TabletsSodium alginate 250mgSodium bicarbonate 106.5mgCalcium carbonate 187.5mg Ireland - English - HPRA (Health Products Regulatory Authority)

gaviscon extra chewable tabletssodium alginate 250mgsodium bicarbonate 106.5mgcalcium carbonate 187.5mg

reckitt benckiser ireland ltd - sodium alginate; sodium bicarbonate; calcium carbonate - chewable tablet - 250 mg/106.5 mg/187.50 milligram(s) - other drugs for peptic ulcer and gastro-oesophageal reflux disease (gord); alginic acid

Lithicarb FC New Zealand - English - Medsafe (Medicines Safety Authority)

lithicarb fc

viatris limited - lithium carbonate 250mg;  ; lithium carbonate 250mg - film coated tablet - 250 mg - active: lithium carbonate 250mg   excipient: carnauba wax clear film coat 5544 lactose monohydrate magnesium stearate maize starch povidone sodium starch glycolate active: lithium carbonate 250mg excipient: carnauba wax diethyl phthalate ethanol hypromellose e-15 lactose monohydrate magnesium stearate maize starch povidone purified water sodium starch glycolate

Gaviscon Peppermint Chewable Tablets Sodium alginate 250mg Sodium hydrogen Carbonate 133.5mgCalcium Carbonate 80mg Ireland - English - HPRA (Health Products Regulatory Authority)

gaviscon peppermint chewable tablets sodium alginate 250mg sodium hydrogen carbonate 133.5mgcalcium carbonate 80mg

reckitt benckiser ireland ltd - sodium alginate; sodium hydrogen carbonate; calcium carbonate - chewable tablet - 250 mg/133.5 mg/80 milligram(s) - other drugs for peptic ulcer and gastro-oesophageal reflux disease (gord); alginic acid

Gaviscon Double Action chewable tablets mint United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

gaviscon double action chewable tablets mint

reckitt benckiser healthcare (uk) ltd - sodium alginate; sodium bicarbonate; calcium carbonate - chewable tablet - 250mg ; 106.5mg ; 187.5mg

LITHSPEN lithium carbonate 250 mg tablet bottle Australia - English - Department of Health (Therapeutic Goods Administration)

lithspen lithium carbonate 250 mg tablet bottle

aspen pharmacare australia pty ltd - lithium carbonate, quantity: 250 mg - tablet, film coated - excipient ingredients: dextrin; lactose monohydrate; macrogol 6000; sodium starch glycollate type a; purified talc; sodium lauryl sulfate; magnesium stearate; hypromellose; maize starch - mania, both as treatment and prophylaxis; manic depressive (bipolar) illness, both as treatment and as prophylaxis; it is less effective in depressive swings. in recurrent endogenous (unipolar) depressive illness, it is highly effective as prophylaxis in a number of cases, and is probably useful as treatment, especially if there is a family history of manic depressive illness and response to lithium. in some cases of schizoaffective illness and so called chronic schizophrenia it is dramatically effective. those in the latter category who do respond have frequently had affective symptoms at some time. it is used in character or personality disorders in young people with clear evidence of cyclothymia. lithium should not be prescribed until it is certain that the manic depressive swings are established and the course of the disease certain. if the patient has two affective swings in one year, perhaps in opposite directions, and associated with a positive family history, it should certainly be seriously considere